Reduced serum levels of miR-218-5p have been proposed as a biomarker for PCa bone metastasis: low miR-218-5p serum levels predict shorter bone metastasis-free survival and correlate with higher PSA and GS compared to non-metastatic or control individuals [64]. This evidence concerns the gene KLK3 and bone metastasis.